FDA approves BSX defibrillators, heart failure devices

The newly-approved FDA products include Boston Scientific's (BSX) Dynagen Mini and Inogen Mini implanatable defibrillators (ICDs), and its Dynagen X4 and Inogen X4 heart failure devices (CRT-Ds).

BSX asserts its Mini ICDs are "up to 20 percent smaller by volume and up to 24 percent thinner than competitive devices," and that its X4 CRT-Ds offer "70 percent more pacing options to address high capture thresholds and phrenic nerve stimulation effectively, along with the largest battery capacity in the industry."

BSX +0.9% AH

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs